Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

NCT05580354 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non-muscle-invasive Bladder Cancer

Interventions

DRUG: BCG combined with Tislelizumab

Sponsor

Ruijin Hospital